Events

Thank you for pointing that out. Here's the corrected version of the article, with all quotes used exactly as written, without any alterations or paraphrasing:

Ecolab Strengthens Board with Appointment of Supply Chain Veteran Marion Gross

SHERIDAN, WYOMING – June 10, 2025 – Ecolab Inc., a global leader in water, hygiene and infection prevention solutions, has appointed Marion Gross, the former Executive Vice President and Global Chief Supply Chain Officer of McDonald’s Corporation, to its board of directors as an independent director. Effective May 7, 2025, Gross also joins the Compensation & Human Capital Management Committee and the Safety, Health & Environment Committee. Her election was confirmed during Ecolab’s Annual Meeting of Stockholders.

Enhancing Strategic Oversight with Global Supply Chain Expertise

SHERIDAN, WYOMING – June 4, 2025 – As global data traffic surges and demands on digital infrastructure intensify, aconnic introduces the ACCEED 8000 platform—a robust 100G networking solution built to address the most pressing performance, scalability, and security challenges across telecom, cloud, healthcare, and industrial sectors.

Designed to support the exponential growth of 5G/6G, IoT, and mission-critical applications, the ACCEED 8000 delivers ultra-low-latency performance, carrier-grade reliability, and future-ready flexibility—all essential for next-generation networking.

Solving Today’s Networking Bottlenecks

Enterprise and service provider networks face unprecedented challenges:

SHERIDAN, WYOMING – June 4, 2025 – Utility companies facing mounting pressure to modernize their critical infrastructure are turning to aconnic’s telecom solutions to overcome legacy system limitations, meet rising bandwidth demands, and achieve regulatory compliance in a fast-evolving landscape.

Legacy systems like TDM and SDH are no longer sufficient to support real-time data, cybersecurity requirements, and the increasing complexity of smart grids and IoT technologies. According to McKinsey, delays in modernizing utility infrastructure could cost the sector as much as $25 billion annually. aconnic’s solutions offer a transformative path forward, enabling seamless migration to IP/Ethernet networks, enhanced network management, and energy-efficient performance—delivering both operational and strategic advantages.

Driving Network Modernization Across the Utilities Sector

SHERIDAN, WYOMING – June 4, 2025 – HUBER+SUHNER is making a powerful statement at ANGA COM 2025 with its comprehensive range of physical layer solutions for high-speed connectivity, addressing the growing needs of the communication market. From advanced fiber optic systems to precision GNSS timing solutions, the company is presenting its latest innovations designed to optimize mobile, fixed, and data center networks.

Driving Innovation Across Mobile, Fixed, and Data Center Networks

At the forefront of connectivity technology, HUBER+SUHNER is demonstrating how its cutting-edge components and systems support mission-critical infrastructure. Visitors at Hall 8, Booth B30 can explore the company’s full suite of solutions for mobile networks, fixed access networks, and hyperscale data centers.

Key offerings include:

SHERIDAN, WYOMING - June 3, 2025 - As global electrification accelerates, HUBER+SUHNER is stepping up to meet the increasing demand for durable, high-performance cable solutions with the launch of its latest innovation: the RADOX® 185 mm² FLEX screened high voltage cable. Engineered for the toughest electric vehicle (EV) environments, this new cable is designed to support the operational demands of heavy-duty applications across mining, agriculture, and marine sectors.

Designed for a High-Stakes EV Future

With electric mining vehicles expected to account for nearly 50% of new sales by 2044, OEMs are under mounting pressure to deploy systems that can withstand extreme mechanical and environmental conditions. The RADOX® 185 mm² FLEX screened cable directly addresses this need, offering superior resilience and flexibility in mission-critical applications.

SHERIDAN, WYOMING – June 3, 2025 – As modern industries demand faster, longer-distance, and interference-free communication systems, RF-over-Fiber (RFoF) technology is gaining traction as a strategic upgrade to conventional coaxial RF connectivity. HUBER+SUHNER, a global leader in high-performance RF and microwave cable solutions, is spearheading innovation in this space, demonstrating how RFoF delivers clear advantages in challenging environments.

Reinforcing the Value of Coaxial RF Cables

Traditional coaxial cables remain a staple in high-frequency signal transmission. Their simple yet effective design—comprising an inner conductor, dielectric insulator, and outer conductor—ensures strong shielding and high signal fidelity. These attributes make coaxial cables a cost-efficient and robust solution, particularly in scenarios where short distances and physical resilience are key.

SHERIDAN, WYOMING – June 3, 2025 – Heidelberger Druckmaschinen AG (HEIDELBERG) has marked a major milestone with the celebration of its 175th anniversary, unveiling the newly redesigned Print Media Center (PMC) – now branded the Home of Print – at its Wiesloch-Walldorf site in Germany. The week-long event welcomed more than 1,500 international guests and reinforced the company’s position as a comprehensive systems integrator in the global printing industry.

Home of Print: Strategic Showcase for Growth and Innovation

The new Home of Print is not only the industry's largest customer demonstration center but also a core component of HEIDELBERG’s long-term growth strategy. The center consolidates the company’s end-to-end solutions across packaging, label, and commercial printing into one cohesive environment.

SHERIDAN, WYOMING – June 3, 2025 – Heidelberger Druckmaschinen AG (HEIDELBERG) has introduced the new Cartonmaster CX 145, a very large format (VLF) sheetfed offset press aimed at the high-growth folding carton printing sector. The move strategically positions HEIDELBERG as a full-range supplier for packaging print solutions, aligning with its long-term growth strategy and marking a significant milestone in its 175th anniversary year.

Strategic Entry into Format Class 6 Press Market

Folding carton printing for food, beverage, and consumer packaging continues to see above-average annual growth, particularly in long-run production using format class 6 (105 cm × 145 cm / 41.34 × 57.09 in) sheetfed offset presses. In response, HEIDELBERG is broadening its packaging portfolio to include this segment.

SHERIDAN, WYOMING – June 1, 2025 – Roche has announced compelling final overall survival data from its phase III INAVO120 study, showing that the Itovebi™ (inavolisib)-based regimen reduces the risk of death by more than 30% in patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer. The findings were presented at the 2025 ASCO Annual Meeting and simultaneously published in the New England Journal of Medicine.

First PI3K Inhibitor to Prolong Survival in This Breast Cancer Subtype

The INAVO120 trial demonstrated that Itovebi, when combined with palbociclib and fulvestrant, achieved a median overall survival (OS) of 34.0 months compared to 27.0 months for the control group receiving palbociclib and fulvestrant alone. This represents a statistically significant and clinically meaningful improvement (HR=0.67; p=0.0190).

SHERIDAN, WYOMING – June 1, 2025 – Roche has announced compelling new data from its ongoing FENopta open-label extension study, confirming that its investigational therapy fenebrutinib continues to provide sustained disease suppression in patients with relapsing multiple sclerosis (RMS) for up to two years.

The 96-week results presented at the CMSC Annual Meeting in Phoenix highlight fenebrutinib’s potential as a first-in-class reversible Bruton’s tyrosine kinase (BTK) inhibitor in the multiple sclerosis space. This development is poised to influence treatment paradigms, particularly as Phase III results approach later this year.

Sustained Disease Control With No Observed Disability Progression

SHERIDAN, WYOMING – May 27, 2025 – Heidelberger Druckmaschinen AG (HEIDELBERG) has launched its 2025/26 financial year with exceptional results, driven by its standout performance at China Print 2025 in Beijing. The company’s strategic emphasis on packaging and digital printing proved highly effective, resulting in the sale of nearly 350 printing units—well above expectations—and setting a solid course for continued growth in the Asian market.

Strong Demand Underscores HEIDELBERG’s Market Leadership

Attracting around 120,000 attendees and over 1.3 million online viewers, China Print reaffirmed its status as the region’s premier print industry event. HEIDELBERG recorded the highest visitor numbers at the show, where customers from across Asia expressed robust interest in the company’s end-to-end printing solutions.

SHERIDAN, WYOMING – May 27, 2025 – In a pivotal move to diversify its production capabilities, Plural Industria Grafica LTDA, one of South America's leading offset printing firms, has integrated sheetfed offset technology from Heidelberger Druckmaschinen AG (HEIDELBERG) into its operations for the first time. This landmark decision underscores Plural's commitment to capturing new market segments and enhancing cost-efficiency for shorter print runs.

Expanding Beyond Traditional Web Offset

Based in Santana de Parnaíba, São Paulo, Plural has long been a dominant force in web offset printing, serving sectors from publishing to commercial and security printing. With its newly installed Speedmaster XL 106-8-P+L and the 100th unit of the fourth-generation CutStar reel sheeter, the company is now targeting previously inaccessible market segments that demand shorter run lengths.

SHERIDAN, WYOMING – May 27, 2025 – Heidelberger Druckmaschinen AG (HEIDELBERG) has successfully navigated a challenging economic landscape, achieving its fiscal year 2024/25 targets while laying the groundwork for further growth in 2025/26. The company maintained a stable adjusted EBITDA margin of 7.1 percent and generated a clearly positive free cash flow of around €50 million, despite rising wage costs, a slightly lower sales volume, and expenses related to the drupa trade fair.

Sales reached approximately €2.28 billion, just under the previous year’s €2.395 billion. The fourth quarter was a standout, with sales accelerating and the adjusted EBITDA margin doubling to around 10 percent compared to the prior year.

Resilient Financial Management and Profitability Focus

SHERIDAN, WYOMING – May 27, 2025 – Seaway Printing has taken a bold step toward fully autonomous production, becoming the first U.S. customer to implement HEIDELBERG’s Plate to Unit system, and integrating the world’s first Inline Splicer with the CutStar generation 4 sheeter. The move is part of a sweeping automation strategy aimed at significantly improving productivity and operational efficiency across Seaway’s expanded Wisconsin facility.

Located in De Pere, Wisconsin, Seaway recently doubled its production capacity to meet surging demand for short-run book and magazine printing. With new HEIDELBERG technology embedded in prepress, press, and postpress operations, the company now operates with fewer manual interventions and has optimized labor usage by allowing each machine to be managed by just one operator.

Breakthrough in Prepress and Plate Logistics

SHERIDAN, WYOMING – May 27, 2025 – Roche has received a significant endorsement from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), which issued a positive opinion for Itovebi™ (inavolisib) in combination with palbociclib and fulvestrant. This recommendation positions Roche to offer a first-line treatment solution for adult patients with PIK3CA-mutated, ER-positive, HER2-negative, locally advanced or metastatic breast cancer—an area with limited current treatment options.

This development is underpinned by data from the phase III INAVO120 study, which demonstrated that the Itovebi-based regimen more than doubled progression-free survival compared to the standard treatment alone. The recommendation marks a key milestone toward potential European Commission approval, with broader implications for treatment standards across the region.

SHERIDAN, WYOMING – May 27, 2025 – Roche has announced a new strategic collaboration with Broad Clinical Labs, aiming to accelerate the adoption of its next-generation Sequencing by Expansion (SBX) technology, with an initial focus on trio-based whole genome sequencing for critically ill newborns and their biological parents. The partnership signifies a pivotal move in expanding genomics-enabled healthcare and precision medicine at scale.

This joint initiative is poised to establish SBX as a clinical mainstay in neonatal intensive care units (NICUs), helping identify genetic disorders in newborns with unprecedented speed and precision. It also positions both organizations to lead in delivering fast, scalable, and cost-efficient genomic insights that could redefine diagnostic and therapeutic practices.

Targeting Transformational Impact in Clinical Genomics

SHERIDAN, WYOMING – May 27, 2025 – Roche has unveiled compelling two-year follow-up data from its pivotal phase III STARGLO trial, reinforcing the long-term clinical value of Columvi® (glofitamab) in combination with chemotherapy for patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). The results underscore the strategic impact of Roche’s bispecific antibody pipeline in addressing aggressive hematologic malignancies with limited treatment options.

Landmark Survival Benefit in R/R DLBCL

The updated STARGLO data show a 40% improvement in overall survival for patients treated with Columvi plus GemOx (gemcitabine and oxaliplatin), compared to the control arm receiving MabThera®/Rituxan® (rituximab) with GemOx. Notably, the median overall survival for the Columvi arm was not reached, versus 13.5 months in the comparator group.

Further findings demonstrated:

SHERIDAN, WYOMING – May 27, 2025 – Roche has received FDA approval for Susvimo® (ranibizumab injection) 100 mg/mL as a new treatment for diabetic retinopathy (DR), marking a pivotal advancement in the battle against this vision-threatening condition that affects nearly 10 million Americans.

The approval makes Susvimo the first and only FDA-approved continuous drug delivery system for DR, offering patients the potential to maintain vision with just one refill every nine months. This development adds a third approved indication for Susvimo, which is already cleared for neovascular or ‘wet’ age-related macular degeneration and diabetic macular edema.

SHERIDAN, WYOMING – May 27, 2025 – Roche has announced an encouraging update on its supplemental Biologics License Application (sBLA) for Columvi® (glofitamab) in combination with gemcitabine and oxaliplatin (GemOx), following discussion by the FDA’s Oncologic Drugs Advisory Committee (ODAC). The combination therapy demonstrated a significant 41% reduction in the risk of death in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) who are not candidates for autologous stem cell transplant.

Landmark survival data in STARGLO trial supports regulatory momentum

SHERIDAN, WYOMING – May 27, 2025 – Roche has announced FDA approval of its VENTANA® MET (SP44) RxDx Assay, marking a major milestone in companion diagnostics for non-small cell lung cancer (NSCLC). This approval paves the way for a more precise identification of patients eligible for AbbVie’s Emrelis™ (telisotuzumab vedotin-tllv), a targeted therapy for non-squamous NSCLC with MET protein overexpression.

Enhancing Treatment Precision in Lung Cancer Care

The VENTANA MET (SP44) RxDx Assay is the first FDA-approved companion diagnostic for detecting MET protein expression in NSQ-NSCLC patients. By identifying those with elevated levels of MET—a key predictive biomarker—the assay supports clinicians in selecting patients who are most likely to benefit from c-Met-targeted therapy.